Onconic Therapeutics said its gastroesophageal reflux disease drug Zacubo (zastaprazan) will be available for broader combination prescriptions after clinical trials confirmed no meaningful drug interactions with four cardiovascular treatments.
The company conducted clinical trials evaluating drug-drug interactions after repeated co-administration of Zacubo with the cardiovascular treatments clopidogrel, aspirin, atorvastatin and apixaban. No clinically significant drug-drug interactions were observed.
Many patients with gastroesophageal reflux disease also have chronic conditions such as cardiovascular disease or dyslipidemia, making it common for them to take multiple medications at the same time. Given the prevalence of polypharmacy among such patients, clinical evidence on combination use is an important factor in prescribing decisions.
In the research, Onconic said the antiplatelet pharmacodynamic response when Zacubo was combined with clopidogrel was similar to that of clopidogrel alone. Pharmacokinetic and pharmacodynamic evaluations in combination trials with aspirin, atorvastatin and apixaban also showed no clinically significant drug interactions.
"We have secured clinical data confirming no drug interactions with all four commonly co-prescribed cardiovascular treatments," Onconic said Wednesday. "Zacubo can now be prescribed in combination for cardiovascular patients suffering from gastroesophageal reflux disease, giving them a new treatment option."
freiheit@heraldcorp.com
